Streetbeat News

Price Targets

SEAT

Morgan Stanley analyst Cameron Mansson-Perrone has initiated coverage on Vivid Seats (NASDAQ:SEAT) with an Equal-Weight rating and a price target of $9.5.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:46 am

ZI

Deutsche Bank analyst Brad Zelnick has downgraded ZoomInfo Technologies (NASDAQ:ZI) from Buy to Hold and set a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:34 am

SIL

Stifel analyst Stephen Soock has downgraded SilverCrest Metals from Buy to Hold and lowered the price target from C$13 to C$8.25.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:33 am

NEWR

Credit Suisse analyst Fred Lee has downgraded New Relic (NEWR) from Outperform to Neutral and lowered the price target from $113 to $87.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:31 am

EL

Citigroup analyst Filippo Falorni has downgraded Estee Lauder Cos (NYSE:EL) from Buy to Neutral and lowered the price target from $240 to $195.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:30 am

RETA

Barclays analyst Carter Gould has downgraded Reata Pharmaceuticals from Overweight to Equal-Weight, while raising the price target from $110 to $172.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:29 am

GS

Atlantic Equities analyst John Heagerty has upgraded Goldman Sachs Gr (NYSE:GS) from Underweight to Neutral and raised the price target from $330 to $351.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:28 am

RMD

RBC Capital analyst Craig Wong-Pan has upgraded ResMed (NYSE:RMD) from Sector Perform to Outperform and raised the price target from $262 to $284.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:27 am

KIDS

Needham analyst Mike Matson has reiterated a 'Buy' rating on OrthoPediatrics (NASDAQ:KIDS) and maintained a $55 price target.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:12 am

HOLX

Needham analyst Mike Matson has reiterated a 'Buy' rating on Hologic (NASDAQ:HOLX) and maintained a price target of $95.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:11 am